Androphilic protein studied histochemically in stage D2 prostatic cancer.
Androphilic protein in prostatic cancer was histochemically observed with dihydrotestosterone (DHT), R 1881, and mibolerone as ligands. Cancer cells were equally stained with fluorescent R 1881 and mibolerone, and this fluorescence seems to be made up of both the androgen receptor and progestin-binding protein. The staining with fluorescent DHT was weak. Sixty-two Stage D2 prostatic cancer patients were examined with histochemical androphilic protein, and they then received endocrine therapy. The presence of fluorescence of R 1881 was not correlated with grade, but a relationship between the presence of fluorescence and the response to endocrine therapy was noticed 6 months after the start of treatment. Moreover, fluorescence-positive patients showed better survival than fluorescence-negative patients. An examination with fluorescent DHT revealed a similar tendency to that of R 1881, but the frequency of positive fluorescence was lower, indicating that R 1881 is a suitable ligand in this type of study.
D000727:Androgen-Binding Protein / Q000378:metabolism*; D001707:Biopsy, Needle; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000031:analogs & derivatives; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005453:Fluorescence; D006651:Histocytochemistry; D006801:Humans; D008024:Ligands; D008297:Male; D009363:Neoplasm Proteins / Q000378:metabolism*; D009367:Neoplasm Staging; D009919:Orchiectomy; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011485:Protein Binding; D013194:Staining and Labeling / Q000379:methods
D000727:Androgen-Binding Protein; D008024:Ligands; D009363:Neoplasm Proteins; D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol; C004955:fosfestrol